Luster v. PuraCap Laboratories, LLC

District Court, D. Delaware·Decided December 1, 2021·No. 1:18-cv-00503·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

) JOSEPH WILLIAM LUSTER, ) ) Plaintiff, ) ) and ) ) SHARON BIGAY LUSTER, ) ) C.A. No. 18-503-MN-JLH Plaintiff-Intervenor, ) ) v. ) ) PURACAP LABORATORIES, LLC, ) ) Defendant. ) ) ) JHL PHARMACEUTICALS, LLC, f/k/a BLU ) PHARMACEUTICALS, LLC, and BLU ) CARIBE, INC., ) ) Plaintiffs, ) ) v. ) C.A. No. 18-553-MN-JLH ) PURACAP LABORATORIES, LLC, AND ) CARIBE HOLDINGS (CAYMAN) CO., ) LTD., ) ) Defendants/Counterclaimants. ) ) ) JOSEPH WILLIAM LUSTER, ) ) Plaintiff, ) ) v. ) C.A. No. 19-1522-MN-JLH ) PURACAP PHARMACEUTICAL, LLC, ) ) Defendant. ) ) MEMORANDUM OPINION

Brian C. Ralston, POTTER ANDERSON CORROON LLP, Wilmington, Delaware. Benjamin J. Lewis, Amanda D. Reed, DENTONS BINGHAM GREENEBAUM LLP, Louisville, Kentucky. Attorneys for Plaintiffs

Brandon W. McCune, BLANK ROME LLP, Wilmington, Delaware. John P. Wixted, Jason A. Snyderman, BLANK ROME LLP, Philadelphia, Pennsylvania. Attorneys for Defendants Vek Jie JENNIFER L. HALL, U.S. MAGISTRATE JUDGE This is the Court’s ruling on Defendants PuraCap Laboratories, LLC, Caribe Holdings (Cayman) Co., Ltd., and PuraCap Pharmaceutical, LLC’s Motion to Enforce Settlement Agreement (C.A. No. 18-503, D.I. 144; C.A. No. 18-553, D.I. 124; C.A. No. 19-1522, 44) and Plaintiff Joseph William Luster’s Motion for Attorneys’ Fees and Costs (C.A. No. 18-503, D.I. 143; C.A. No. 19-1522, D.I. 41).! I held a hearing on the pending motions on October 7, 2021. (“Tr. __.”) For the reasons stated below, Defendants’ motion is GRANTED-IN-PART and DENIED-IN-PART, and Plaintiff Luster’s motion is DENIED. 1. BACKGROUND These three cases arise from Plaintiffs’ 2016 sale of a pharmaceutical business to Defendants PuraCap Laboratories, LLC (“PuraCap Labs”), PuraCap Phamaceutial LLC (“PuraCap Pharma”), and Caribe Holdings Co. (“Caribe”). The transaction included an Asset Purchase Agreement and a Consulting Agreement. (See D.I. 58, Ex. 1.) After Defendants failed to perform in accordance with those agreements, Plaintiffs filed three separate suits: (1) a breach of contract action against PuraCap Labs for failure to pay certain Performance Compensation Payments due under the Consulting Agreement (C.A. No. 18-503 (“Consulting Agreement Case”); (2) the same breach of contract claim against PuraCap Pharma, as PuraCap Labs’ contractual guarantor (C.A. No. 19-1522 (“Guaranty Case”)); and (3) an action seeking a declaration that certain funds placed in escrow pursuant tothe Asset Purchase Agreement should be released to an LLC controlled by Mr. Luster (C.A. No. 18-553 (“Escrow Case’”)).

' The parties have consented to disposition of the motions by a Magistrate Judge. C.A.No. 18-503, 148, 162; C.A. No. 18-553, D.I. 126; C.A. No. 19-1522, DI. 46, 60; see 28 U.S.C. § 636(c)(1); Fed. R. Civ. P. 73. Unless otherwise indicated, further citations to the docket refer to C.A. No. 18-503.

In March 2021, the parties to the Consulting Agreement Case and the Guaranty Case agreed to the entry of consent judgments in favor of Mr. Luster. (C.A. No. 18-503, D.I. 134, 137; C.A. No. 19-1522, D.I. 34, 35.) On March 25, 2021, a “Final Judgment in Favor of Plaintiff Joseph William Luster” was entered in both cases. It stated, in pertinent part:

1. Judgment is entered in favor of Plaintiff Joseph William Luster (“Mr. Luster”), and jointly and severally against Defendants PuraCap Laboratories LLC (“PuraCap Labs”) and PuraCap Pharmaceutical LLC (collectively the “PuraCap Defendants”), in the amount of $2,024,218.19; 2. Within thirty (30) days of entry of this Judgment, Mr. Luster may submit a Bill of Costs, and may also file a motion for entry of a supplemental judgment seeking an additional award of prejudgment interest and attorneys’ fees, and to determine post- judgment interest rates; 3. This Judgment is entered in satisfaction of all Performance Compensation Payments and Base Fees claimed by Mr. Luster through March 31, 2020 pursuant to his March 31, 2016 Consulting Agreement with PuraCap Labs. For the avoidance doubt, this Judgment precludes any additional claims by Mr. Luster to any compensation under the Consulting Agreement (including any compensation related to claims for alleged wrongful termination) that allegedly became due and owing prior to March 31, 2020. . . .

(D.I. 137.)2 Meanwhile, the parties continued to litigate the Escrow Case, which concerned $1,902,944.87 that had been placed in escrow in connection with the Asset Purchase Agreement. Defendants claimed that Plaintiffs JHL Pharmaceuticals, LLC and Blu Caribe, Inc. (collectively, the “Blu Parties”) were not entitled to the escrow funds because the property was in materially worse shape than Mr. Luster had represented and encumbered by liens from invoices that Mr. Luster had failed to pay. (C.A. No. 18-553, D.I. 62.)

2 A separate consent judgement was entered in the Consulting Agreement Case in favor of Plaintiff-Intervenor Sharon Bigay Luster. (D.I. 136.) On the eve of trial in the Escrow Case, the parties participated in a settlement conference moderated by the trial judge. It is undisputed that, prior to and during the settlement conference, Defendants represented that they were unable to pay the consent judgment from the Consulting Agreement and Guaranty cases in a lump sum, and Defendants threatened to declare bankruptcy

if Mr. Luster attempted to immediately collect those funds. (D.I. 145, Ex. 2 ¶ 4; D.I. 146, Ex. 5 ¶ 20.) After negotiations, Plaintiff Mr. Luster, Plaintiffs Blu Parties,3 and Defendants agreed on terms to resolve the Escrow Case as well as open issues in the Consulting Agreement and Guaranty Cases (including Mr. Luster’s ability to seek attorney’s fees and interest in those cases). A term sheet was circulated, which provided (in its entirety) as follows: 18-553 Escrow Action 18-503 Performance Compensation Action 19-1522 Guarant[y] Action [1] Parties agree to split the funds in the escrow account equally, and both parties will instruct the escrow agent to release the funds. If the funds are released on or before Friday April 9, 2021, the parties will inform the court. If the funds are not released on or before Friday April 9, 2021 and assuming Plaintiff has instructed the escrow agent to release them, the parties will contact the court and request that the court enter a consent judgment awarding $1.8 million dollars to Plaintiff (Blu Parties). [2] The doxycycline ANDA and the plant will be used to securitize the consent judgment. The specifics will be further determined by the parties and their counsel. [3] The parties will release all claims for attorneys’ fees related to the 18-553 case and the 18-503 and 19-1522 cases for which a consent judgment was previously entered by the court. [4] As a payment plan for the $2,024,218.19 consent judgment in favor of Bill Luster in the 18-503 and 19-1522 cases, PuraCap will pay Bill Luster $1 million within 7 days of receiving the funds from the escrow account. The remaining amount of $1,024,218.19 will be paid over a period of 18 months with a 3% interest rate, the calculation of which shall be agreed upon. Bill

3 Plaintiff-Intervenor Sharon Luster did not participate in the settlement conference, nor is she a party to any of the pending motions. Luster will release claims for pre-judgment interest and post- judgment interest in the 18-503 and 19-1522 cases, subject to reinstatement should the balance of $1,024,218.19 plus interest not be paid within 5 days of the end of the 18 month term. Should pre- and post-judgment interest become an issue, the parties may submit papers to the Court regarding the correct amounts for each.

Free access — add to your briefcase to read the full text and ask questions with AI

Luster v. PuraCap Laboratories, LLC, (D. Del. 2021).

Luster v. PuraCap Laboratories, LLC (Luster v. PuraCap Laboratories, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Town of Newton v. Rumery
480 U.S. 386 (Supreme Court, 1987)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
American Eagle Outfitters v. Lyle & Scott Ltd.
584 F.3d 575 (Third Circuit, 2009)
Continental Insurance v. Rutledge & Co.
750 A.2d 1219 (Court of Chancery of Delaware, 2000)
Estate of Osborn Ex Rel. Osborn v. Kemp
991 A.2d 1153 (Supreme Court of Delaware, 2010)
Norton v. Poplos
443 A.2d 1 (Supreme Court of Delaware, 1982)
Equitable Trust Co. v. Gallagher
99 A.2d 490 (Supreme Court of Delaware, 1953)
Stephenson v. Capano Development, Inc.
462 A.2d 1069 (Supreme Court of Delaware, 1983)
Prairie Capital III, L.P. v. Double E Holding Corp.
132 A.3d 35 (Court of Chancery of Delaware, 2015)
Transcent Management Consulting, LLC v. Bouri
152 A.3d 108 (Supreme Court of Delaware, 2016)
Tiernan v. Devoe
923 F.2d 1024 (Third Circuit, 1991)